en · de · es · fr · pt
methods-notes.peptides6579.com › Data › Analytical Methods And Storage Stability — Quick Reference

Analytical Methods And Storage Stability — Quick Reference

By Editorial Desk · published 2026-05-25 · last reviewed 2026-07-12 · Data

If you have been reading about Peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Methods And Storage Stability

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Storage, Analysis, and Regulatory Status

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank at a glance

PropertyValueNotes
Typical storage temperature-20 °C or belowFor lyophilized powder, long term
Common analytical methodReverse-phase HPLCUsually paired with mass spectrometry
Typical reported purityAt or above 95 percent by areaResearch-grade material
Aqueous solubilityHighSolutions used in laboratory assays
Moisture sensitivityHydrolyzes in solutionAseptic handling reduces degradation

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Related pages on this site

Selank Origin and Chemical Identity

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Background and Molecular Identity

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Administration, Testing and Availability

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Reference notes

== Construction of PAM matrices == PAM matrices were introduced by Margaret Dayhoff in 1978. The calculation of these matrices was based on 1572 observed mutations in the phylogenetic trees of 71 families of closely related proteins. The proteins to be studied were selected on the basis of having high similarity with their predecessors. The protein alignments included were required to display at least 85% identity. As a result, it is reasonable to assume that any aligned mismatches were the result of a single mutation event, rather than several at the same location. Each PAM matrix has twenty rows and twenty columns — one representing each of the twenty amino acids translated by the genetic code. The value in each cell of a PAM matrix is related to the probability of a row amino acid before the mutation being aligned with a column amino acid afterwards. From this definition, PAM matrices are an example of a substitution matrix.

which can be understood as converting kinetic energy to work, was largely the result of Gaspard-Gustave Coriolis and Jean-Victor Poncelet over the period 1819–1839. The former called the quantity quantité de travail (quantity of work) and the latter, travail mécanique (mechanical work), and both championed its use in engineering calculations. In the paper Über die Natur der Wärme (German "On the Nature of Heat/Warmth"), published in the Zeitschrift für Physik in 1837, Karl Friedrich Mohr gave one of the earliest general statements of the doctrine of the conservation of energy: "besides the 54 known chemical elements there is in the physical world one agent only, and this is called Kraft [energy or work]. It may appear, according to circumstances, as motion, chemical affinity, cohesion, electricity, light and magnetism; and from any one of these forms it can be transformed into any of the others."

Majority (about 70% to 80%) is converted to bicarbonate ions (HCO3–) by the enzyme carbonic anhydrase in the red blood cells, by the reaction: CO2 + H2O → H2CO3 → H+ + HCO3– 5–10% is dissolved in blood plasma 5–10% is bound to hemoglobin as carbamino compounds Hemoglobin, the main oxygen-carrying molecule in red blood cells, carries both oxygen and carbon dioxide. However, the CO2 bound to hemoglobin does not bind to the same site as oxygen. Instead, it combines with the N-terminal groups on the four globin chains. However, because of allosteric effects on the hemoglobin molecule, the binding of CO2 decreases the amount of oxygen that is bound for a given partial pressure of oxygen. This is known as the Haldane Effect, and is important in the transport of carbon dioxide from the tissues to the lungs. Conversely, a rise in the partial pressure of CO2 or a lower pH will cause offloading of oxygen from hemoglobin, which is known as the Bohr effect.

Sources: en.wikipedia.org

Reference notes

=== Seamless === Seamless steel belts are suitable for the production of high-quality plastic foils and films, such as optical and packaging films. The thickness of these belts typically ranges from 0.03 to 0.60 mm (or 0.012 to 0.23 in.). They are particularly useful for machines with narrow drum diameters that require the use of wide belts.

Energy column The column labeled "energy" denotes the energy equivalent of (the mass of a neutron minus the mass per nucleon), that is of the mass defect with respect to the neutron, in MeV. Use of the neutron as reference guarantees all nuclides will have a positive value. Mathematically: mn − mnuclide / A. Note that this means that a higher "energy" value actually means that the nuclide has a lower energy. Inversely the mass is A (mn − E / k) where E is the energy, mn is 1.0086649159 and k = 931.4941037 MeV (energy equivalent of the dalton). Omitted if there is no experimental mass determination within 0.0001.

== Properties == The human CRHR2 gene contains 12 exons. Three major functional isoforms, alpha (411 amino acids), beta (438 amino acids), and gamma (397 amino acids), encoded by transcripts with alternative first exons, differ only in the N-terminal sequence comprising the signal peptide and part of the extracellular domain (amino acids 18-108 of CRHR2 alpha); the unique N-terminal sequence of each isoform (34 amino acids in CRHR2 alpha; 61 amino acids in Hs CRHR2 beta; 20 amino acids in CRHR2 gamma) is followed by a sequence common to all isoforms (377 amino acids) comprising most of the multi-pass transmembrane domain followed by a cytoplasmic domain of 47 amino acids. CRHR2 beta is expressed in the human brain; CRHR2 alpha predominates in peripheral tissues. The N-terminal signal peptides of corticotropin-releasing hormone receptor 1 and CRHR2 beta are cleaved off in the endoplasmic reticulum to yield the mature receptors. In contrast, CRHR2 alpha contains a unique pseudo signal peptide that is not removed from the mature receptor. In adenylate cyclase activation assays, CRH-related peptides are 10 times more potent at stimulating CRHR2 beta than CRHR2 alpha and CRHR2 gamma, suggesting that the N-terminal sequence is involved in the ligand-receptor interaction.

=== Greek === Greek critic Dimitris Danikas gave Dogtooth a rating of eight out of ten ("with enthusiasm"), calling it "black, surreal, nightmarish" and writing that Dogtooth is as important for Greek cinema as Theodoros Angelopoulos's 1970 film Reconstitution. Danikas added, "Lanthimos composes and goes from one level to another like a wildcat-creator, constantly and continuously maintaining the same rigorous style. Hence the aphasia; hence the uniformity; hence the submission and the scheduled mass culture; hence also the serial killer; hence, however, the disobedience, the anarchy. As I said at the beginning: Dogtooth has the surrealism of Buñuel, the scalpel of Haneke, the underground horror of a thriller without the splatter. Perfect." Danikas characterized Dogtooth's Academy Award nomination as "the greatest Greek triumph of recent years." Columnist Dimitris Bouras, writing for Kathimerini, mentioned "the beneficial effects that the prestigious award could have" and wrote that the nomination reveals three interesting facts: "1) in Greece we need to be extroverts (and not only in cinema), 2) exportable product is whatever has an identity, 3) Dogtooth's nomination is like an investment‍— manna from the heaven of Hollywood for the developing Greek cinema."

Sources: en.wikipedia.org

Frequently asked questions

How is Selank detected in a laboratory?

The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.

What storage conditions are typical for Selank?

Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.

Does high reported purity guarantee correct identity?

No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.

How should the powder be stored?

Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.

Network